Administering particular compounds against various parasites, mycoplasmas, other indications and other infections
OwnerPatrick T. Prendergastinventor
Life of this patent
Estimating the term…
Abstract
One or more compounds are administered against one or more kinds of parasites and/or one or more diseases caused by such parasites, against one or more kind of Mycoplasma and/or one or more diseases caused by such Mycoplasmas and/or against one or more of the following indications or infections (a) hairy leukoplakia, (b) oral candidosis, (c) mouth ulcerations-aphthous/herpetic/bacterial, (d) fungal candida, (e) human papilloma virus, (f) molluscum contagiosum, (g) squamous oral carcinoma, (h) Kaposi's sarcoma oral lesions, (i) periodontitis, (j) necrotizing gingivitis, (k) orofacial herpes zoster, and (1) rotaviruses. The present invention furthermore provides specific formulations including such compound(s).
Claims21
A method of treating a human or animal suffering from a haemoflagellate parasitic infection comprising administering to a human or animal who has been infected with a haemoflagellate parasite an effective amount of a pharmaceutical formulation comprising a compound, or a physiologically acceptable salt thereof, selected from the group having the formula:
- ##STR6## wherein:
- R.sub.1 =H, R.sub.2 =CH.sub.3, R.sub.3 =CH.sub.3 and R.sub.4 =H, or
- R.sub.1 =H or CH.sub.3 S and ##STR7## and R.sub.5 =CH.sub.3, Cl, OH or a monophosphate group
- R.sub.5 =CH.sub.3, CH.sub.2 OH or Cl
- R.sub.7 =H or Br
- or R.sub.1 =H and ##STR8## and X.sub.1 and X.sub.2 are independently selected from H, methyl, ethyl, hydroxyl, the halogens and carboxyl ##STR9## or R.sub.8 =(CH.sub.2).sub.7 CH.sub.3 ;
- and R.sub.2 =OH and R.sub.3 =OH, monophosphate, diphosphate or triphosphate group
- or R.sub.2 and R.sub.3 are linked to form a 3', 5'-(cyclic monophosphate derivative,
- or a metabolite of said compound, said metabolite being a member of the group consisting of:
- N.sup.6 -(.DELTA..sup.2 -isopentenyl) adenine;
- 6-N-(3-methyl-3-hydroxybutylamino) purine;
- Adenine;
- Hypoxanthine;
- Uric Acid;
- and
- Methylated xanthines.
A method of treating a human or animal suffering from a haemoflagellate parasitic infection comprising administering to a human or animal who has hd an abnormal level of a haemoflagellate parasite an effective amount of a pharmaceutical formulation comprising a compound, or a physiologically acceptable salt thereof, selected from the group having the formula:
- ##STR10## wherein:
- R.sub.1 =H, R.sub.2 =CH.sub.3, R.sub.3 =CH.sub.3 and R.sub.4 =H, or
- R.sub.1 =H or CH.sub.3 S and ##STR11## and R.sub.5 =CH.sub.3, Cl, OH or a monophosphate group
- R.sub.6 =CH.sub.3, CH.sub.2 OH or Cl
- R.sub.7 =H or Br
- or R.sub.1 =H and ##STR12## and X.sub.1 and X.sub.2 are independently selected from H, methyl, ethyl, hydroxyl, the halogens and carboxyl ##STR13## or R.sub.8 =(CH.sub.2).sub.7 CH.sub.3 and R.sub.2 =OH and R.sub.3 =OH, monophosphate, diphosphate or triphosphate group
- or R.sub.2 and R.sub.3 are linked to form a 3', 5'-cyclic monophosphate derivative,
- or a metabolite of said compound, said metabolite being a member of the group consisting of:
- N.sup.6 -(.DELTA..sup.2 -isopentenyl) adenine;
- 6-N-(3-methyl-3-hydroxybutylamino) purine;
- Adenine;
- Hypoxanthine;
- Uric Acid;
- and
- Methylated xanthines.
A method of treating a human or animal suffering from a Mycoplasma infection comprising administering to a human or animal who has been infected with Mycoplasma an effective amount of a pharmaceutical formulation comprising a compound, or a physiologically acceptable salt thereof, selected from the group having the formula:
- ##STR14## wherein:
- R.sub.1 =H, R.sub.2 CH.sub.3, R.sub.3 =CH.sub.3 and R.sub.4 =H, or
- R.sub.1 =H or CH.sub.3 S and ##STR15## and R.sub.5 =CH.sub.3, Cl, OH or a monophosphate group
- R.sub.6 =CH.sub.3, CH.sub.2 OH or Cl
- R.sub.7 =H or Br
- or R.sub.1 =H and ##STR16## and X.sub.1 and X.sub.2 are independently selected from H, methyl, ethyl, hydroxyl, the halogens and carboxyl ##STR17## or R.sub.8 =(CH.sub.2).sub.7 CH.sub.3 ;
- and R.sub.2 =OH and R.sub.3 =OH, monophosphate, diphosphate or triphosphate group
- or R.sub.2 and R.sub.3 are linked to form a 3', 5'-cyclic monophosphate derivative or a metabolite of said compound, said metabolite being a member of he group consisting of:
- N.sup.6 -(.DELTA..sup.2 -isopentenyl) adenine;
- 6-N-(3-methyl-3-hydroxybutylamino) purine;
- Adenine;
- Hypoxanthine;
- Uric Acid;
- and
- Methylated xanthines.
The method recited in claim 10, wherein said Mycoplasma is selected from the group consisting of Mycoplasma athritidis, Mycoplasma fermentans and Mycoplasma incognitus.
A method comprising administering to a blood sample containing parasite an effective amount of a pharmaceutical formulation comprising a compound, or a physiologically acceptable salt thereof, selected from the group having the formula:
- ##STR18## wherein:
- R.sub.1 =H, R.sub.2 =CH.sub.3, R.sub.3 =CH.sub.3 and R.sub.4 =H, or
- R.sub.1 =H or CH.sub.3 S and ##STR19## and R.sub.5 =CH.sub.3, Cl, OH or a monophosphate group
- R.sub.6 =CH.sub.3 CH.sub.2 OH or Cl
- R.sub.7 =H or Br
- or R.sub.1 =H and ##STR20## and X.sub.1 and X.sub.2 are independently selected from H, methyl, ethyl, hydroxyl, the halogens and carboxyl ##STR21## or R.sub.8 =(CH.sub.2).sub.7 CH.sub.3 ;
- and R.sub.2 =OH and R.sub.3 =OH, monophosphate, diphosphate or triphosphate group
- or R.sub.2 and R.sub.3 are linked to form a 3', 5'-cyclic monophosphate derivative,
- or a metabolite of said compound, said metabolite being a member of the group consisting of:
- N.sup.6 -(.DELTA..sup.2 -isopentenyl) adenine;
- 6-N-(3-methyl-3-hydroxybutylamino) purine;
- Adenine;
- Hypoxanthine;
- Uric Acid;
- and
- Methylated xanthines.
A method comprising administering to a blood sample containing mycoplasma an effective amount of a pharmaceutical formulation comprising a compound, or a physiologically acceptable salt thereof, selected from the group having the formula:
- ##STR22## wherein:
- R.sub.1 =H, R.sub.2 =CH.sub.3, R.sub.3 =CH.sub.3 and R.sub.4 =H, or
- R.sub.1 =H or Ch.sub.3 S and ##STR23## and R.sub.5 =Ch.sub.3, Cl, OH or a monophosphate group
- R.sub.6 =CH.sub.3, CH.sub.2 OH or Cl
- R.sub.7 =H or Br
- or R.sub.1 =H and ##STR24## and X.sub.1 and X.sub.2 are independently selected from H, methyl, ethyl, hydroxyl, the halogens and carboxyl ##STR25## or R.sub.8 =(CH.sub.2).sub.7 CH.sub.3 ;
- and R.sub.2 =OH and R.sub.3 =OH, monophosphate, diphosphate or triphosphate group
- or R.sub.2 and R.sub.3 are linked t form a 3', 5'-cyclic monophosphate derivative,
- or a metabolite of said compound, said metabolite being a member of the group consisting of:
- N.sup.6 -(.DELTA..sup.2 -isopentenyl) adenine;
- 6-N-(3-methyl-3-hydroxybutylamino) purine;
- Adenine;
- Hypoxanthine;
- Uric Acid;
- and
- Methylated xanthines.
A method of treating a human or animal who has been exposed to the risk of haemoflagellate parasitic infection comprising administering to a human or animal who has been exposed to the risk of haemoflagellate parasitic infection an effective amount of a pharmaceutical formulation comprising a compound, or a physiologically acceptable salt thereof, selected from the group having the formula:
- ##STR26## wherein:
- R.sub.1 =H, R.sub.2 =CH.sub.3, R.sub.3 =CH.sub.3 and R.sub.4 =H, or
- R.sub.1 =H or Ch.sub.3 S and ##STR27## and R.sub.5 =CH.sub.3, Cl, OH or a monophosphate group
- R.sub.5 =CH.sub.3, CH.sub.2 OH or Cl
- R.sub.7 =H or Br
- orR.sub.1 =H and ##STR28## and X.sub.1 and X.sub.2 are independently selected from H, methyl, ethyl, hydroxyl, the halogens and carboxyl ##STR29## or R.sub.8 =(CH.sub.2).sub.7 CH.sub.3 ;
- and R.sub.2 =OH and R.sub.3 =OH, monophosphate, diphosphate or triphosphate group
- or R.sub.2 and R.sub.3 are linked to form a 3', 5'-(cyclic monophosphate derivative,
- or a metabolite of said compound, said metabolite being a member of the group consisting of:
- N.sup.6 -(.DELTA..sup.2 -isopentenyl) adenine;
- 6-N-(3-methyl-3-hydroxybutylamino) purine;
- Adenine;
- Hypoxanthine;
- Uric Acid;
- and
- methylated xanthines.
A method of treating a human or animal who has been exposed to the risk of a Mycoplasma infection comprising administering to a human or animal who has been exposed to the risk of Mycoplasma infection an effective amount of a pharmaceutical formulation comprising a compound, or a physiologically acceptable salt thereof, selected from the group having the formula:
- ##STR30## wherein:
- R.sub.1 =H, R.sub.2 CH.sub.3, R.sub.3 =CH.sub.3 and R.sub.4 =H, or
- R.sub.1 =H or CH.sub.3 S and ##STR31## and R.sub.5 =CH.sub.3, Cl, OH or a monophosphate group
- R.sub.6 =CH.sub.3, Ch.sub.2 OH or Cl
- R.sub.7 =H or Br
- orR.sub.1 =H and ##STR32## and X.sub.1 and X.sub.2 are independently selected from H, methyl, ethyl, hydroxyl, the halogens and carboxyl ##STR33## or R.sub.8 =(CH.sub.2).sub.7 CH.sub.3 ;
- and R.sub.2 =OH and R.sub.3 =OH, monophosphate, diphosphate or triphosphate group
- or R.sub.2 and R.sub.3 are linked to form a 3', 5'-cyclic monophosphate derivative,
- or a metabolite of said compound, said metabolite being a member of the group consisting of:
- N.sup.6 -(.DELTA..sup.2 -isopentenyl) adenine;
- 6-N-(3-methyl-3-hydroxybutylamino) purine;
- Adenine;
- Hypoxanthine;
- Uric Acid;
- and
- Methylated xanthines.
Dependencies are inferred from the claim text.